Refined study of the interaction between HIV-1 p6 late domain and ALIX
- Carine Lazert†1,
- Nathalie Chazal†2,
- Laurence Briant2,
- Denis Gerlier1 and
- Jean-Claude Cortay1Email author
© Lazert et al; licensee BioMed Central Ltd. 2008
Received: 06 December 2007
Accepted: 13 May 2008
Published: 13 May 2008
The interaction between the HIV-1 p6 late budding domain and ALIX, a class E vacuolar protein sorting factor, was explored by using the yeast two-hybrid approach. We refined the ALIX binding site of p6 as being the leucine triplet repeat sequence (Lxx)4 (LYPLTSLRSLFG). Intriguingly, the deletion of the C-terminal proline-rich region of ALIX prevented detectable binding to p6. In contrast, a four-amino acid deletion in the central hinge region of p6 increased its association with ALIX as shown by its ability to bind to ALIX lacking the proline rich domain. Finally, by using a random screening approach, the minimal ALIX391–510 fragment was found to specifically interact with this p6 deletion mutant. A parallel analysis of ALIX binding to the late domain p9 from EIAV revealed that p6 and p9, which exhibit distinct ALIX binding motives, likely bind differently to ALIX. Altogether, our data support a model where the C-terminal proline-rich domain of ALIX allows the access of its binding site to p6 by alleviating a conformational constraint resulting from the presence of the central p6 hinge.
A variety of enveloped viruses use for budding the host machinery that is required for the inward vesiculation of the membrane of the multivesicular bodies (MVB) . For HIV-1 virus, this process is in part mediated through physical interactions between the viral Gag-p6 late domain and the host cellular factors Tsg101 (tumor suppressor gene 101) [2–6], and AIP1/ALIX (ALG-2 interacting protein X) [4, 6].
In this context, the reduction of Tsg101 levels by siRNA or the introduction of a dominant-negative Tsg101 mutant severely blocks viral budding [7, 8], while the disruption of the p6-ALIX interaction is less detrimental to HIV-1 budding. In EIAV, another member of the lentivirus subfamily of retrovirus, the Gag-p9 late domain contains a unique ALIX-binding motif (YPDL), which supports the release of virions in the absence of the Tsg101 cofactor.
Mechanistically, the interaction between p6 and Tsg101 is well-characterized: Tsg101 interacts with the p6 PTAP motif via its N-terminal UEV domain in a process that appears to be up-regulated when p6 becomes monoubiquitinylated at conserved Lys residues in positions 27 and 33 [3, 7, 9, 10]. The structure of the Tsg101 UEV domain in complex with a 9-amino acid p6 peptide containing a central PTAP motif has been solved in solution by RMN [11, 12].
The other p6-interacting partner, ALIX, which consists of 868 amino acids, is organized in three domains: (i) a N-terminal BroI domain responsible for CHMP4 recruitment in the endosomal pathway [13, 14], (ii) a middle region (aa. 362–702), which interacts in vivo with p6 and p9 late domains , and (iii) a long C-terminal proline-rich region (PRR) that binds to Tsg101 . Based on recent crystallographic data, the ALIX central region has been shown to adopt a "V" shape, which is the result of the complex arrangement of 11 α-helices with connecting loops that cross three times between the two arms of the V [16, 17]. When overexpressed in mammalian cells, the V domain strongly inhibits HIV-1 particles release, and this inhibition is reversed by mutations of amino acid residues that specifically block binding of the ALIX V domain to p6 .
By using an in vitro pull-down approach, Strack et al., (2003)  have noted that the affinity of EIAV p9 for ALIX was significantly higher than that of HIV-1 p6. This suggests that the presence of a more efficient ALIX-binding site in p9 may compensate for the absence of a Tsg101 binding site. Such differences could be due in part to some intrinsic properties of the p6 polypeptide: (i) the p9 EIAV prototype motif L/IYPxL of different Gag late domains recognized by ALIX is only partially conserved in Gag-p6, where an adjacent LxxLF motif seems important for binding and, (ii) p6 adopts a random conformation in water without any preference for secondary structure . However, under more hydrophobic conditions, i.e. in the presence of 50% aqueous TFE, p6 exhibits a functional helix-flexible-helix conformation, as assessed by its ability to bind to the Vpr protein .
The following work revealed that specific p6-ALIX association could be achieved through contacts between a minimal ALIX fragment containing amino acids residues 391–510 in the long arm of the V domain and a p6 late domain which has been mutated in its central hinge region. This mutant which displayed intermediary affinity for ALIX compared to HIV-1 p6 wild type and EIAV p9, suggests that in physiological conditions the constrained conformation of the HIV-1 late domain weakens its association with ALIX.
Yeast two-hybrid analysis of the HIV-1 p6-ALIX interaction
Several studies concerning the in vivo interaction between EIAV p9 and ALIX were previously designed using the Y2H assay [15, 21]. For comparison, we examined for the first time the HIV-1 p6-ALIX interaction using a similar approach. Close characterization of the ALIX-binding site in HIV-1 p6 was accomplished by systematically introducing alanine mutations at every amino acid residue contained within the p6 minimal region (aa: 31–46) that had been previously implicated in ALIX recognition . These Gal4 DBD-p6 bait constructs were individually co-transformed into the yeast strain AH 109 with a prey plasmid encoding the ALIX protein (868 amino acid-long) fused to the Gal4 AD. Relative quantification of the protein/protein interaction strength was monitored by measuring the β-galactosidase activity in yeast cells cotransformed with bait and prey expressing plasmids.
In subsequent experiments, we tested in the Y2H system the potential interaction between the p6 domain and different ALIX mutant constructs. Side-by-side comparison was carried out in the presence of the EIAV p9 domain. Unexpectedly, a truncation of the proline-rich region in ALIX (ALIXΔPRR) from amino acids 716 to 868 impaired ALIX binding to p6 in vivo, while p9 still bound to the ALIX mutant (Fig. 1B). Because in vitro ALIX deleted from PRR has a lower affinity for p6 than for p9 (dissociation constants measured by SPR are 60 μM and 1.2 μM, respectively) , our data point out to a major role of PRR as positive regulator for the ALIX-p6 interaction.
The region 541 to 582 contains essentially helix-7 residues in the arm 1 of the V domain (nomenclature is from ) and could play a key role in ALIX oligomerization. Indeed, bioinformatic analyses using the MultiCoil prediction program  suggested that this region in ALIX has a high probability for forming a trimeric coiled-coil (with a maximum trimeric residue probability value of 0.691 for S575). Y2H analysis of ALIXΔ541–582 (Fig. 1B) provides evidence that helix 7 (and probably oligomerization of ALIX protein) is dispensable for interaction with p6 and/or p9 in vivo.
From structural studies, the ALIX viral late domain-binding site has been mapped to a large hydrophobic pocket on the long arm of the V domain. Mutational experiments targeting amino acid residues, which form the surrounding walls, revealed in particular that substitutions V509A in α5 and F676D in α11 caused a dramatic effect on the ability of the protein to bind a p6-derived peptide in vitro .
The effect of these two mutations on interaction with p6 and p9 was evaluated in vivo using the Y2H assay. As expected, both the V509A and F676D mutations prevented the yeast cell growth on selective medium when tested against the bait-p6 protein (Fig. 1B). Quite different results were obtained with p9, since the V509A mutation was well tolerated. Taken together, these results are consistent with a model in which the intact conformation of the binding site is required for the efficient interaction between ALIX and the helix-2 amino acid residues in the HIV-1 p6 late domain. In this regard, it has been postulated that p6 may bind coaxially to the V domain hydrophobic pocket and form a four-helix bundle together with ALIX α- 4, α- 5 and α- 11 . The molecular mechanisms by which p9 binds to ALIX are likely involving a less stringent process in terms of structural requirement and integrity of the late domain binding site. Indeed, the short YPDL tetrapeptide motif detected in p9 constitutes a specific binding epitope for AIP1 family members throughout the eukaryotic evolution . Moreover, this motif appears very stringent since the close YLDL motif within the Sendai virus M protein, binds to the Bro1 domain of ALIX between amino acid residues 1–211, i.e. outside of the p9 binding domain .
Description of a HIV-1 p6 mutant with increased ALIX-binding affinity
Therefore a p6 mutant deleted for amino-acids S25 to Q28 (see location in Fig. 2A) referred as p6ΔSQKQ was produced and was tested for interaction with ALIX by the Y2H assay. p9-ALIX, p6-ALIX, and p6ΔSQKQ-ALIX gave rise to detectable growth on selective media when incubated for 3 days at 30°C, indicating that protein-protein interaction has occurred (Fig. 2B). The binding affinity quantified by in situ α-galactosidase staining using X-α-Gal as a substrate revealed a quite stronger interaction between p6ΔSQKQ-ALIX as compared to p6-ALIX and/or p9-ALIX. When tested for binding to the truncated ALIXΔPRR, the p6ΔSQKQ mutant supported significant growth on selective media. α-galactosidase staining was however reduced as compared to that observed in yeast co-expressing p9. Under similar conditions, the p6-ALIXΔPRR cotransfectants were found unable to grow as expected from data described in Figure 1. The absence of a significant growth on selective media of yeast co-expressing p9-Gal4AD, p6-Gal4AD, p6ΔSQKQ-Gal4AD and ALIX-Gal4DBD ruled out the possibility that the different bait and prey proteins tested could directly activate the Gal4 responsive promoter and thus validated the specificity of the above described interactions.
To confirm these data, GST-pull down assays were then carried out with extracts from cells expressing either ALIX-HA or ALIXΔPRR-HA. This truncation was used because the removal of the proline-rich region has been described to improve the efficiency of in vitro interaction . After their expression in E. coli, the following fusion proteins, GST, GST-p6, GST-p9 and GST-p6ΔSQKQ were bound to glutathione-Sepharose beads, and allowed to interact with either ALIX-HA or ALIXΔPRR-HA. After extensive washings, the complexes were eluted, subjected to electrophoresis under denaturing conditions, transferred to a PVDF membrane and reacted with an anti-HA monoclonal antibody. As shown in Figure 2C, the three GST constructs bound to both ALIX-HA and ALIXΔPRR-HA proteins in the following strength order: GST-p9>GST-p6ΔSQKQ>GST-p6 while the control GST displayed no detectable binding activity.
The overexpression of wild type ALIX has been shown to partially rescue budding defects of HIV-1 particles with a p6 domain containing mutations in the PTAP motif (called PTAP/LIRL), i.e. unable to recruit the ESCRT I component Tgs101 [17, 21]. We therefore tested the ability of ALIX to alleviate the release defect of HIV-1 PTAP/LIRL mutated viruses containing or not the SQKQ deletion. We used a previously described complementation assay [6, 21]: HIV-1 proviral plasmid (NLδp6) that lacks the p6 domain was cotransfected into 293T with a plasmid expressing a truncated HIV-1 Gag protein (Gagδp6) fused to either the PTAP/LIRL p6 domain or the PTAP/LIRL p6ΔSQKQ domain of HIV-1, together with an expression vector for ALIX or empty vector. As shown in Figure 2D, the coexpression of ALIX led to an increase in viral particle production and infectivity by both HIV-1 PTAP/LIRL p6 virus and HIV-1 PTAP/LIRL p6ΔSQKQ. Similar effect of ALIX on PTAP/LIRL p6ΔSQKQ was observed, although with reduced efficiencies. In summary, the deletion amino acid residues located in the p6 hinge region (ΔSQKQ) enhanced binding to ALIX, and partially allowed the rescue of HIV-1 PTAP/LIRL upon ALIX overexpression. This limited enhancing effect of this deletion on HIV-1 PTAP/LIRL p6 upon ALIX overexpression is indicative of a negative modulation played by the hinge region of HIV-1 p6. This negative modulation would be part of the highly complex process that optimises the HIV-1 budding.
Mapping of a minimal p6ΔSQKQbinding site within the middle region of ALIX
If HIV-1 budding process is dependent on the presence of both Tsg101 and ALIX proteins, ALIX recruitment by the p6 late domain occurs at relatively low levels. On an evolutionary point of view, it has been proposed  that a strong ALIX-binding site in combination with a Tsg101-binding site may confer a disadvantage to HIV-1 perhaps because hyperactivation of ALIX can lead to apoptosis . We identified here what makes p6 a weak ALIX-binding factor. The ALIX-binding site in p6 includes the consensus YPxnL sequence inserted into a leucine triplet repeat motif (Lxx)4. By contrast to p9, p6 is unable to bind to a detectable level to a truncated form of ALIX deleted from its PRR (aa: 716–868). Beside the essential role of the C-terminus of the ALIX PRR in recruiting the ESCRT machinery to promote HIV-1 budding , our data support that the PRR could also facilitate the recruitment of p6. The distinct behaviour of the p6ΔSQKQ mutant, which still binds to ALIXΔPRR, sheds some light on a particular structural aspect of p6. Indeed, analyzing HIV-1 subtypes sequenced until now, the p6 domain appears by far the most variable domain in the Gag polyprotein precursor and natural deletions or insertions are frequently observed in the central region of p6 between S14 and I31 . Interestingly, mutation of the 27KQE29 motif has never been observed so far. If K27 residue in this motif is a substrate for ubiquitin modification , it is unclear whether Gag itself needs to be ubiquitinylated for budding. The hinge region of p6 adopts a constrained conformation, which prevents optimum binding to ALIX. The deletion of the hinge region that encompasses the highly conserved KQE motif results in an increased affinity of the mutant late domain for ALIX probably by alleviating the bend between N and C terminus of p6. As suggested by in vivo analysis, a tightly interaction between late domain inhibited partially rescue of particle production upon ALIX over-expression. We can speculate that the ALIX-binding site is not necessarily optimized for high-affinity particularly in the context of HIV-1 which employs two late domains. Taken together, these observations point out that the negative activity of the p6 hinge may provide an additional ALIX-dependent regulatory process in the mechanisms that control HIV-1 budding, the complexity of which is far from being fully understood as shown by the recent finding of nucleocapsid binding to ALIX . Finally, by using a random strategy, we have refined the p6ΔSQKQ and p9 binding site down to the ALIX 391–510 fragment. Furthermore, from our data, both HIV-1 p6 and EIAV p9 bind to an overlapping site on ALIX but in a quite different way. If the interaction between ALIX and p9 is direct, that of p6 to ALIX occurs in two steps. We propose that the PRR domain of ALIX could first contact p6 so as to alleviate the conformational constraints of the p6 hinge region and enable the subsequent binding of the HIV-1 late domain to the ALIX V domain within the 391–510 fragment.
During the submission of this work the crystal structures of ALIX V domain in complex with short peptides spanning the HIV-1 and EIAV late-domain motifs was reported . Because p6 and p9 peptides, but not the full-length proteins, bind ALIX V domain with similar affinities, the authors proposed that interactions of ALIX with full-length p6 and p9 are regulated by subtle protein context-dependent effects. Our work based on Y2H experiments provides further support to biosensor experiments reported by Zhai et al.  and validates a model in which the structural constraints in the hinge region of p6 weaken the binding of the HIV-1 late domain to ALIX. Accordingly, the interaction of p6 late domain with ALIX appears to be a finely tuned process required for optimal budding of HIV-1.
DNA binding domain
equine infectious anemia virus
human immunodeficiency virus type-1
surface plasmon resonance
We thank C. Leroux and O. Vincent for providing the molecular clone of EIAV and plasmid pGAD ALIX, respectively, P. Bieniasz for providing plasmid constructs NLδp6 and Gagδp6 used in complementation experiments. This work was supported by the CNRS, ANRS and the Ministère de la Recherche.
- Katzmann DJ, Babst M, Emr SD: Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell. 2001, 106 (2): 145-155. 10.1016/S0092-8674(01)00434-2.View ArticlePubMedGoogle Scholar
- Fujii K, Hurley JH, Freed EO: Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1. Nat Rev Microbiol. 2007, 5 (12): 912-916. 10.1038/nrmicro1790.View ArticlePubMedGoogle Scholar
- Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG, Sundquist WI: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 2001, 107 (1): 55-65. 10.1016/S0092-8674(01)00506-2.View ArticlePubMedGoogle Scholar
- Strack B, Calistri A, Craig S, Popova E, Gottlinger HG: AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell. 2003, 114 (6): 689-699. 10.1016/S0092-8674(03)00653-6.View ArticlePubMedGoogle Scholar
- VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA: Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A. 2001, 98 (14): 7724-7729. 10.1073/pnas.131059198.PubMed CentralView ArticlePubMedGoogle Scholar
- von Schwedler UK, Stuchell M, Muller B, Ward DM, Chung HY, Morita E, Wang HE, Davis T, He GP, Cimbora DM, Scott A, Krausslich HG, Kaplan J, Morham SG, Sundquist WI: The protein network of HIV budding. Cell. 2003, 114 (6): 701-713. 10.1016/S0092-8674(03)00714-1.View ArticlePubMedGoogle Scholar
- Demirov DG, Ono A, Orenstein JM, Freed EO: Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A. 2002, 99 (2): 955-960. 10.1073/pnas.032511899.PubMed CentralView ArticlePubMedGoogle Scholar
- Martin-Serrano J, Zang T, Bieniasz PD: HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med. 2001, 7 (12): 1313-1319. 10.1038/nm1201-1313.View ArticlePubMedGoogle Scholar
- Demirov DG, Orenstein JM, Freed EO: The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol. 2002, 76 (1): 105-117. 10.1128/JVI.76.1.105-117.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Myers EL, Allen JF: Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag. J Virol. 2002, 76 (22): 11226-11235. 10.1128/JVI.76.22.11226-11235.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Pornillos O, Alam SL, Davis DR, Sundquist WI: Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat Struct Biol. 2002, 9 (11): 812-817.PubMedGoogle Scholar
- Pornillos O, Alam SL, Rich RL, Myszka DG, Davis DR, Sundquist WI: Structure and functional interactions of the Tsg101 UEV domain. Embo J. 2002, 21 (10): 2397-2406. 10.1093/emboj/21.10.2397.PubMed CentralView ArticlePubMedGoogle Scholar
- Katoh K, Shibata H, Suzuki H, Nara A, Ishidoh K, Kominami E, Yoshimori T, Maki M: The ALG-2-interacting protein Alix associates with CHMP4b, a human homologue of yeast Snf7 that is involved in multivesicular body sorting. J Biol Chem. 2003, 278 (40): 39104-39113. 10.1074/jbc.M301604200.View ArticlePubMedGoogle Scholar
- Kim J, Sitaraman S, Hierro A, Beach BM, Odorizzi G, Hurley JH: Structural basis for endosomal targeting by the Bro1 domain. Dev Cell. 2005, 8 (6): 937-947. 10.1016/j.devcel.2005.04.001.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen C, Vincent O, Jin J, Weisz OA, Montelaro RC: Functions of early (AP-2) and late (AIP1/ALIX) endocytic proteins in equine infectious anemia virus budding. J Biol Chem. 2005, 280 (49): 40474-40480. 10.1074/jbc.M509317200.View ArticlePubMedGoogle Scholar
- Fisher RD, Chung HY, Zhai Q, Robinson H, Sundquist WI, Hill CP: Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell. 2007, 128 (5): 841-852. 10.1016/j.cell.2007.01.035.View ArticlePubMedGoogle Scholar
- Lee S, Joshi A, Nagashima K, Freed EO, Hurley JH: Structural basis for viral late-domain binding to Alix. Nat Struct Mol Biol. 2007, 14 (3): 194-199. 10.1038/nsmb1203.PubMed CentralView ArticlePubMedGoogle Scholar
- Munshi UM, Kim J, Nagashima K, Hurley JH, Freed EO: An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J Biol Chem. 2007, 282 (6): 3847-3855. 10.1074/jbc.M607489200.View ArticlePubMedGoogle Scholar
- Stys D, Blaha I, Strop P: Structural and functional studies in vitro on the p6 protein from the HIV-1 gag open reading frame. Biochim Biophys Acta. 1993, 1182 (2): 157-161.View ArticlePubMedGoogle Scholar
- Fossen T, Wray V, Bruns K, Rachmat J, Henklein P, Tessmer U, Maczurek A, Klinger P, Schubert U: Solution structure of the human immunodeficiency virus type 1 p6 protein. J Biol Chem. 2005, 280 (52): 42515-42527. 10.1074/jbc.M507375200.View ArticlePubMedGoogle Scholar
- Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD: Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci U S A. 2003, 100 (21): 12414-12419. 10.1073/pnas.2133846100.PubMed CentralView ArticlePubMedGoogle Scholar
- Wolf E, Kim PS, Berger B: MultiCoil: a program for predicting two- and three-stranded coiled coils. Protein Sci. 1997, 6 (6): 1179-1189.PubMed CentralView ArticlePubMedGoogle Scholar
- Vincent O, Rainbow L, Tilburn J, Arst HN, Penalva MA: YPXL/I is a protein interaction motif recognized by aspergillus PalA and its human homologue, AIP1/Alix. Mol Cell Biol. 2003, 23 (5): 1647-1655. 10.1128/MCB.23.5.1647-1655.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Irie T, Shimazu Y, Yoshida T, Sakaguchi T: The YLDL sequence within Sendai virus M protein is critical for budding of virus-like particles and interacts with Alix/AIP1 independently of C protein. J Virol. 2007, 81 (5): 2263-2273. 10.1128/JVI.02218-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen M, Cortay JC, Logan IR, Sapountzi V, Robson CN, Gerlier D: Inhibition of ubiquitination and stabilization of human ubiquitin E3 ligase PIRH2 by measles virus phosphoprotein. J Virol. 2005, 79 (18): 11824-11836. 10.1128/JVI.79.18.11824-11836.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Gottlinger HG: How HIV-1 hijacks ALIX. Nat Struct Mol Biol. 2007, 14 (4): 254-256. 10.1038/nsmb0407-254.View ArticlePubMedGoogle Scholar
- Sadoul R: Do Alix and ALG-2 really control endosomes for better or for worse?. Biol Cell. 2006, 98 (1): 69-77. 10.1042/BC20050007.View ArticlePubMedGoogle Scholar
- Usami Y, Popov S, Gottlinger HG: Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site. J Virol. 2007, 81 (12): 6614-6622. 10.1128/JVI.00314-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Peters S, Munoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, Larder B, Cmarko D, Fakan S, Meylan P, Telenti A: Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol. 2001, 75 (20): 9644-9653. 10.1128/JVI.75.20.9644-9653.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Ott DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE: Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus. J Virol. 1998, 72 (4): 2962-2968.PubMed CentralPubMedGoogle Scholar
- Popov S, Popova E, Inoue M, Gottlinger HG: Human immunodeficiency virus type 1 Gag engages the Bro1 domain of ALIX/AIP1 through the nucleocapsid. J Virol. 2008, 82 (3): 1389-1398. 10.1128/JVI.01912-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhai Q, Fisher RD, Chung HY, Myszka DG, Sundquist WI, Hill CP: Structural and functional studies of ALIX interactions with YPX(n)L late domains of HIV-1 and EIAV. Nat Struct Mol Biol. 2008, 15 (1): 43-49. 10.1038/nsmb1319.View ArticlePubMedGoogle Scholar
- Cook RF, Leroux C, Cook SJ, Berger SL, Lichtenstein DL, Ghabrial NN, Montelaro RC, Issel CJ: Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J Virol. 1998, 72 (2): 1383-1393.PubMed CentralPubMedGoogle Scholar
- Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR: Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989, 77 (1): 51-59. 10.1016/0378-1119(89)90358-2.View ArticlePubMedGoogle Scholar
- Martin-Serrano J, Zang T, Bieniasz PD: Role of ESCRT-I in retroviral budding. J Virol. 2003, 77 (8): 4794-4804. 10.1128/JVI.77.8.4794-4804.2003.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.